September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Evolution of Short-wavelength Autofluorescence changes in Central Serous Chorioretinopathy over 12 months.
Author Affiliations & Notes
  • Marta Zola
    Moorfields Eye Hospital, London, United Kingdom
  • Priyanka Sanghi
    University College London, Institute of Ophthalmology, London, United Kingdom
  • Namritha Patrao
    Moorfields Eye Hospital, London, United Kingdom
  • Deepthy Menon
    Moorfields Eye Hospital, London, United Kingdom
  • Philip Hykin
    NIHR Moorfields Biomedical Research Center, London, United Kingdom
  • Sobha Sivaprasad
    NIHR Moorfields Biomedical Research Center, London, United Kingdom
  • Footnotes
    Commercial Relationships   Marta Zola, None; Priyanka Sanghi, None; Namritha Patrao, None; Deepthy Menon, None; Philip Hykin, Allergan (C), Allergan (F), Bayer (C), Bayer (F), Novartis (C), Novartis (F); Sobha Sivaprasad, Allergan (C), Allergan (F), Bayer (C), Bayer (F), Novartis (C), Novartis (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3398. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marta Zola, Priyanka Sanghi, Namritha Patrao, Deepthy Menon, Philip Hykin, Sobha Sivaprasad; Evolution of Short-wavelength Autofluorescence changes in Central Serous Chorioretinopathy over 12 months.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3398.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Short-wavelength autofluorescence (SW-AF) is a useful tool to assess the integrity of the retinal pigment epithelial cells (RPE). The health of the RPE in central serous chorioretinopathy (CSC) is often assessed by SW-AF. However, changes of SW-AF over time may help determine prognosis. In this study, we evaluated the changes in SW-AF over 12 months in different forms of CSC.

Methods : We retrospectively reviewed SW-AF images of 263 eyes with acute, recurrent and chronic CSC over 12 months. SW-AF patterns were broadly classified into normal, reduced signal in areas of subretinal fluid (SRF), stippled hyperautofluorescent in areas of past or current SRF, plaque like confluent absent autofluorescence, granular hypoautofluorescence, stippled hyper- and hypoautofluorescence and tracts. Dome shaped macula and optic disc pits were excluded. Changes in proportion of each SW-AF pattern over 12 months are reported.

Results : In acute CSC (n=23), the most common pattern was reduced signal in areas of SRF (n=21, 91%), other patterns were normal. 22% of these patients (n=5) converted to stippled hyperautofluorescence in the same area over time. No eyes converted to hypoautofluorescence. In recurrent and chronic CSR (n=240), the most frequent pattern at baseline was a stippled hyper and hypoautofluorescent pattern (n=148, 62%) followed by confluent granular hypoautofluorescence (n=53, 22%), confluent plaque like hypoautofluorescence (n=33, 14%) and normal (n=6, 2%). Tracts were present in 53 eyes (22%). At 12 months, 4 out of the 6 eyes (67%) with normal baseline AF worsened to granular hypoautofluorescence. None of the other patterns of AF changed over 12 months but the areas of hyper- and hypoautofluorescence in the stippled variety changed over time with 15% of existing patterns progressing to involve larger areas in eyes with recurrent and chronic CSC.

Conclusions : Acute CSC does not convert to hypoautofluorescent patterns within 12 months of presentation. In chronic and recurrent CSC the patterns of autofluorescence at baseline do not change over 12 months but worsening of the same pattern may be seen by 12 months.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×